BEAM Q4 2024 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M-90.5% YoY

Gross Profit

-$71M-237.4% margin

Operating Income

-$100M-332.7% margin

Net Income

-$90M-300.5% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

+110.7%

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$79M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$370M

Stockholders' Equity

$734M

Cash & Equivalents

$282M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$316M	-90.5%
Gross Profit	-$71M	$176M	-140.5%
Operating Income	-$100M	$133M	-175.3%
Net Income	-$90M	$143M	-163.3%